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1684-1182/Copyright ª 2015, TaiwanAbstract Background: Cytomegalovirus (CMV) is a major pathogen causing significant mortal-
ity and morbidity in immunocompromised hosts. It is important to find risk factors associated
with CMV viremia and its outcome.
Methods: We investigated the incidence, time of onset, risk factors for CMV viremia, and char-
acteristics of CMV diseases in 57 pediatric patients receiving hematopoietic stem cell trans-
plantation (HSCT). Between August 2011 and March 2014, cases of pediatric HSCT patients
at the National Taiwan University Children’s Hospital were reviewed. Viremia was identified
by plasma CMV real-time polymerase chain reaction (RT-PCR) assay.
Results: Eighteen (32%) of the 57 patients developed CMV viremia at a median of 23 days post-
HSCT (range 3 to þ721 days). Eighty-nine percent (16/18) of CMV viremia occurred within
100 days posttransplantation. Four patients finally had CMV diseases (1 with CMV colitis and
3 with CMV pneumonitis) and one patient died of CMV pneumonitis complicated with pulmo-
nary hemorrhage and sepsis. Significant risk factors associated with CMV viremia via univariate
analysis include older age (pZ 0.03), leukemic patients [odds ratio (OR): 5.2, 95% confidence
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cell transplantation patients, JournapZ 0.002), antithymoglobulin (ATG) use before transplantation (OR: 5.09, 95% CI: 1.52w16.9,
p Z 0.007), graft-versus-host disease (GvHD) (OR: 10.1, 95% CI: 2.7w38.7, p < 0.001), and
gastrointestinal GvHD (OR: 10.9, 95% CI: 2.72w43.9, p Z 0.001).
Conclusion: In pediatric posttransplantation patients, CMV viremia mostly occurred within 100
days after transplantation. Risk factors associated with CMV viremia include older diagnostic
age, leukemic patients, unrelated donor HSCT, pretransplant ATG use, GvHD, and gastrointes-
tinal GvHD.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cytomegalovirus (CMV), is a virus which belongs to the
human herpesviruses, betaherpesviruses. It is a major
pathogen causing significant mortality in immunocompro-
mised hosts, such as prematurity and posttransplantation
patients.1,2 From previous studies, the incidence of CMV
viremia in pediatric post bone marrow transplantation pa-
tients was variable, from 12.8% to 41%.2e5 The clinical
manifestations of CMV infection range from asymptomatic
infection, that is, active CMV replication in the blood in the
absence of clinical symptoms or organ failure, to CMV dis-
ease, characterized by CMV infection with systemic end-
organ involvement.5
Previous known risk factors of CMV reactivation were
CMV serostatus, transplantation type, T-cell depletion
regimen, and graft-versus-host-disease (GvHD) develop-
ment.3,4,6,7 The objective of this retrospective study was to
evaluate the incidence and timing of CMV viremia in a pe-
diatric population who had received hematopoietic stem
cell transplantation (HSCT). The risk factors for CMV
viremia were studied and characteristics of CMV disease are
described.
Patients and methods
Study design and data collection
This study was approved by the ethics committee of Na-
tional Taiwan University Hospital, Taiwan. We retrospec-
tively reviewed 57 pediatric patients receiving HSCT at the
National Taiwan University Hospital during August 2011 to
March 2014. No intervention or clinical specimen was
collected from patients. All of the information of the pa-
tients in this study was obtained from medical records. We
collected their demographics, underlying diseases, seros-
tatus, HSCT type and post-HSCT condition, antithymoglo-
bulin (ATG) use, medications, and outcomes.
Identifications and definitions
Currently, quantitative polymerase chain reaction (PCR)
assays of plasma samples have become the most common
way in the determination of viral load during CMV infection
of transplant patients. In this study, CMV real-time PCR (RT-
PCR) was performed for quantitation of plasma CMV viremiau J-L, et al., Risk factors and outc
l of Microbiology, Immunology anand bronchoalveolar lavage fluid using COBAS AmpliPrep/
COBAS TaqMan CMV Test (Roche Molecular Systems, Inc.,
Branchburg, NJ, USA), the first U.S. Food and Drug Admin-
istration (FDA)-approved assay. The quantitated cut-off
level of this method was 150 copies/mL. CMV viremia was
defined by positive CMV-specific RT-PCR in plasma. Since
conditioning chemotherapy of these patients, plasma CMV
PCR was checked by weekly surveillance, which would
continue until patients were discharged or had a negative
plasma CMV PCR result.
Diagnosis of CMV disease was based on positive CMV
viremia and either one of the following: the presence of
appropriate symptoms (fever, and/or organ associated
symptoms, such as cough/diarrhea, etc.) combined with a
positive CMV RT-PCR from the coherent specimen (e.g.,
pneumonia with positive CMV RT-PCR from bronchoalveolar
lavage fluid), or a tissue biopsy specimen that was CMV-
positive by either culture or immunohistochemical
staining.2,8,9
Statistical analysis
All analyses were performed using PASW version 18.0 (SPSS,
Chicago, IL, USA). Comparisons between the CMV viremia
group and nonviremia group were performed using the
Mantel-Haenszel chi-square test for categorical variables to
calculate odds ratio (OR) and 95% confidence interval (CI)
and using the Mann-Whitney U test and Wilcoxon signed
rank test for continuous variables. Multivariate analysis was
performed using multiple logistic regression. A p
value < 0.05 was considered to be statistically significant.
All results of significance are reported as two-tailed.
Results
Demographics
From August 2011 to March 2014, 60 patients who received
HSCTwere initially reviewed in the pediatric department of
National Taiwan University Hospital. However, three pa-
tients were excluded: one patient had disease relapse on
posttransplantation Day þ27 and finally expired due to
Gram-negative bacteria sepsis, and the other two patients
experienced severe sepsis immediately after HSCT and
expired on posttransplantation Day þ9 and Day þ28,
respectively. Therefore, a total of 57 patients wereomes of cytomegalovirus viremia in pediatric hematopoietic stem
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.011
Figure 1. Distributions of underlying diseases. a Retinoblas-
toma, mediastinal tumor, rhabdomyosarcoma. b Thalassemia,
anaplastic anemia, red cell aplasia, myelodysplasia. c Severe
combined immunodeficiency, osteopetrosis. ALL Z acute
lymphoblastic leukemia; AML Z acute myeloid leukemia.
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their age ranged from 0 years to 20 years at disease diag-
nosis in the pediatric hemato-oncological ward of National
Taiwan University Hospital. The mean age  standard de-
viation of patients was 8.1  5.9 years (range 0e20 years).
The male to female ratio was 1.2 (31 men, 26 women).
Patients’ demographic data are shown in Table 1.
Patients’ underlying diseases are shown in Figure 1. The
majority (56%) of patients had hematological diseases,
including acute lymphoblastic leukemia (33%), acute
myeloid leukemia (14%), and other hematological diseases,
such as aplastic anemia, red cell aplasia, myelodysplasia,
and thalassemia (9%). In addition, other diagnoses included
two (3%) of brain tumor, three (5%) of other solid tumors
(retinoblastoma, mediastinal tumor, and rhabdomyosar-
coma), and two (3%) of others, including severe combined
immunodeficiency and osteopetrosis.
CMV viremia
Thirty-two percent (18/57) of patients developed CMV
viremia at a median of 23 days post-HSCT (range from Day
3 to Day þ721). Eighty-nine percent (16/18) of the CMV
viremia occurred in the early posttransplantation period
(<100 days). In viremia patients, the initial viral load
ranged from 1.5  102 copies/mL to 2.2  106 copies/mL.
One patient developed late-onset CMV viremia on post-
transplantation Day þ721 and he had the highest initial
viral load (2.2  106 copies/mL) among viremia patients.
Of these 18 viremia patients, 44% (8/18) did not receive
antiviral treatment and 56% (10/18) did: 17% (3/18)
received ganciclovir treatment, 6% (1/18) had ganciclovir
plus foscarnet, 22% (4/18) received ganciclovir plus CMV
immunoglobulin, and 11% (2/18) received intravenous
immunoglobulin treatment. Only one patient received fos-
carnet because of marked myelosuppression after ganci-
clovir use and there was no clinical evidence of ganciclovir-
resistant CMV in these 10 patients. After the anti-CMVTable 1 Baseline characteristics and distribution of risk factors
Viremia (n Z 18) Non
Mean age of diagnosis (y) 10.9  6.3 6.8
Mean HSCT age (y) 12.6  6.9 8.7
Sex (%)
Female 8 (44) 18 (
Male 10 (56) 21 (
Diagnosis (%)
Leukemia 13 (72) 13 (
Others 5 (28) 26 (
HSCT type (%)
Allo-PBSCTa 17 (95) 21 (
Auto-PBSCT 1 (5) 18 (
Antithymoglobulin (ATG) use (%)
Yes 12 (67) 11 (
GvHD (%) 14 (78) 11 (
GI aGvHD (%) 10 (56) 4 (1
a acute.
aGvHD Z acute graft versus host disease; CI Z confidence interva
GvHD Z graft-versus-host-disease; OR Z odds ratio; PBSCT Z periph
Please cite this article in press as: Wu J-L, et al., Risk factors and outc
cell transplantation patients, Journal of Microbiology, Immunology antreatment, their CMV viral load decreased significantly
(p Z 0.037 using the Wilcoxon signed rank test).
Figure 2 demonstrates the trend of average CMV viral
load in treated and nontreated patients. Due to PCR
equipment limits, viral load <150 copies/mL or undetect-
able was defined as 0 copies/mL in the figure. In these two
groups, high viral load was most frequently found within 3
months after transplantation. In Figure 2, a total of eight
treated patients and eight nontreated patients were
recorded. Data of two treated patients were not shown in
the figure due to late-onset of CMV viremia. In the treatedviremia (n Z 39) OR 95% CI p
 5.3 0.03
 5.8 0.08
0.57
46)
54)
5.2 1.52w17.7 0.008
33)
67)
14.57 1.76w120.5 0.002
54)
46)
5.09 1.52w16.9 0.007
28)
28) 10.1 2.7w38.7 < 0.001
0) 10.9 2.72w43.9 0.001
l; GI aGvHD Z gastrointestinal acute graft versus host disease;
eral blood stem cell transplantation.
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Figure 2. Viral load in treated and nontreated patients after
transplantation. Numbers of each point in the figure were
recorded in the following:
Number of patients in each point of treated and nontreated
patients
Weeks after HSCT 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Treated (n) 8 8 8 8 8 8 7 6 6 5 5 4 4 2 2
Nontreated (n) 8 0 8 8 7 6 6 5 6 6 6 6 8 4 4
HSCT Z hematopoietic stem cell transplantation.
Table 2 Cytomegalovirus (CMV) serostatus and viral load
of 18 viremic patients
CMV serostatus Initial viral load [median,
range (copies/mL]
p
De/Re (n Z 1) 2700
De/Rþ (n Z 7) 3.9  102, 283e150,000 0.24
Dþ/Rþ (n Z 10) 5.8  103, 152e120,000
CMV serostatus Highest viral load [median,
range (copies/mL)]
p
De/Re (n Z 1) 7500
De/Rþ (n Z 7) 1.39  105, 4450e3,000,000 0.11
Dþ/Rþ (n Z 10) 1.9  104, 356e27,000,000
De Z donor seronegative; Dþ Z donor seropositive;
Re Z recipient seronegative; Rþ Z recipient seropositive.
4 J.-L. Wu et al.
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cited in the figure legend. Patient numbers fluctuated for
reasons such as patient’s death or some interrupted data.
The average initial viral loads in the treated and nontreated
groups were 2  104 copies/mL (range, 315e120,000
copies/mL) and 2.6  104 copies/mL (range, 152e150,000
copies/mL), respectively. The average highest viral loads in
treated and nontreated groups were 3.8  106 copies/mL
(range, 550e27,000,000 copies/mL) and 1.2  105 copies/
mL (range, 356e620,000 copies/mL), respectively. There
was no significant difference in the initial and highest viral
load between these two groups (p Z 0.85 and p Z 0.72,
respectively).
Of 18 viremia patients, nine patients expired: two pa-
tients died of disease progression with complications such
as sepsis and gastrointestinal bleeding, three died of sepsis
(2 with documented pathogens), two died of disease pro-
gression, one died of progressive lung GvHD with respira-
tory failure, and one died of CMV pneumonia complicated
with pulmonary hemorrhage and sepsis.
In this study, a high prevalence of pretransplant CMV
seropositivity was found in recipients, overall up to 82% (47/
57), with 86% (19/22) in 0e6-year-olds, 83% (10/12) in 6e12-
year-olds, and 87% (20/23) in >12-year-olds. A total of 17
(17/18, 94%) recipients with CMV viremia were initially CMV-
seropositive. Only one (1/18, 6%) seronegative recipient in
viremic patients received autologous transplantation.Risk factors associated with CMV viremia
CMV serostatus and viral load of 18 viremic patients are
shown in Table 2. Only one patient was CMV serologically
negative who had undergone autologous HSCT. The other
two groups of CMV serostatus, De/Rþ (donor-seronegative/
recipient-seropositive) and Dþ/Rþ (donor-seropositive/
recipient-seropositive), consisted of seven patients and 10Please cite this article in press as: Wu J-L, et al., Risk factors and outc
cell transplantation patients, Journal of Microbiology, Immunology anpatients, respectively. There was no statistical influence by
donor or recipient serostatus on the initial and highest viral
load (p Z 0.24 and p Z 0.11, respectively). Risk factors
associated with CMV viremia are summarized in Table 1. Sex
distribution in the two groups was similar, with 44% female
in the viremia group and 46% female in the nonviremia
group. The mean age of diagnosis of the viremia and the
nonviremia group was 10.9  6.3 years and 6.8  5.3 years,
respectively (pZ 0.03). As for diagnosis, leukemia patients
carried a greater risk of CMV viremia (OR Z 5.2, 95% CI
1.52w17.7, p Z 0.008). Ninety-five percent (17/18) of pa-
tients of the viremia group received allo-peripheral blood
stem cell transplantation (PBSCT), which increased the risk
of CMV viremia (OR Z 14.57, 95% CI 1.76w120.5;
p Z 0.002). Sixty-seven percent (12/18) of patients of the
viremia group had pretransplantation ATG use which was
also a risk factor (ORZ 5.09, 95% CI 1.52w16.9, pZ 0.007).
Seventy-eight percent (14/18) of patients of the viremia
group had more than one kind of GvHD (OR Z 10.1, 95% CI
2.7w38.7, pZ < 0.001). Gastrointestinal GvHD was another
risk factor (OR Z 10.9, 95% CI 1.72w43.9, p Z 0.001),
whereas skin GvHD showed no statistical significance.
Multivariate analyses were also performed, but did not show
statistical evidence for these factors.
CMV disease
Clinical features of the four patients with CMV disease are
shown in Table 3. One patient developed CMV colitis and
the other three developed CMV pneumonia, which
accounted for 7% (4/57) in post-HSCT patients. Initial viral
load of these four patients ranged from 3.1  102 copies/
mL to 3.6  103 copies/mL, similar to the other 14
asymptomatic CMV viremia patients (p Z 0.67). As for the
highest CMV viral load, it ranged from 3.6  103 copies/mL
to 3  106 copies/mL in CMV disease patients; from the 14
patients with only viremia, the highest CMV viral load
ranged from 3.5  102 copies/mL to 2.7  107 copies/mL
(p Z 0.67). Three patients with CMV disease were diag-
nosed with hematological malignancy. All of these four
patients were allogeneic HSCT recipients, had positive CMV
serology before transplantation, and experienced acute
GvHD.omes of cytomegalovirus viremia in pediatric hematopoietic stem
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.011
Table 3 Characteristics of four cytomegalovirus (CMV) disease patients
Patient 1 Patient 2 Patient 3 Patient 4
Diagnosis Hodgkin lymphoma ALL AML MDS
Diagnostic age (y) 18 10 0.3 20
Age at BMT (y) 22.08 11.75 0.95 24.36
Conditioning regimen Carmustine, etoposide,
Ara-C, melphalana
Busulfan,
cyclophosphamideb
Busulfan,
cyclophosphamide
Busulfan,
cyclophosphamide
BMT type allo allo allo allo
ATG use Yes Yes Yes No
D/R CMV serology Dþ/Rþ De/Rþ De/Rþ De/Rþ
Onset of viremia(d) 49 34 11 126
CMV disease Colitis Pneumonitis Pneumonitis Pneumonitis
GvHD GI Grade I GI Grade I
Skin Grade I
Liver Grade I
GI Grade I
Skin Grade II
Liver Grade I
Skin Grade I
Suspicious GI GvHD
Treatment Ganciclovir
Foscarnet
Ganciclovir
CMV-Ig
Ganciclovir
CMV-Ig
Ganciclovir
Outcome Expired Alive Expired Alive
Cause of death PDRAB sepsis Pulmonary
hemorrhage, sepsis
a Carmustine 300 mg/m2/dose QD for 1 day; etoposide 200 mg/m2/dose QD for 4 days; Ara-C 200 mg/m2/dose bid for 4 days; melphalan
140 mg/m2/dose for 1 day.
b Busulfan 4 mg/kg/day for 4 days (5 mg/kg/day if patient <6 years old); cyclophosphamide 60 mg/kg/day for 2 days.
ALL Z acute lymphoblastic leukemia; AML Z acute myeloid leukemia; Ara-C Z cytarabine; ATG Z antithymoglobulin; BMT Z bone
marrow transplantation; CMV Z cytomegalovirus; CMV-Ig Z cytomegalovirus immune globulin; D Z donor; GI Z gastrointestinal;
GvHD Z graft versus host disease; MDS Z myelodysplastic syndrome; MUD Z matched unrelated donor; PDRAB Z pan-drug resistant
Acinetobacter baumannii; QD Z daily; R Z recipient.
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tioning chemotherapy with busulfan and cyclophospha-
mide, pretransplantation ATG, and developed acute
gastrointestinal GvHD. All received ganciclovir treatment.
Two of them died: one died of CMV pneumonitis compli-
cated with pulmonary hemorrhage and sepsis, and the
other died of pan-drug resistant Acinetobacter baumannii
sepsis. As for the other 14 asymptomatic patients with
viremia, eight of them (43%) received treatment.
With regards to risk factors of developing CMV disease,
there was no statistically significant difference between he-
matological malignancy, HSCT type, ATG usage, and GvHD.Discussion
Infection is always a major issue for post-HSCT patients and
CMV plays a major role in viral infection in pediatric post-
HSCT patients. Among the 57 pediatric post-HSCT patients
involved in this study, from August 2011 to March 2014, a
high incidence (32%) of CMV viremia was found. Eighty-nine
percent of CMV viremia occurred within the early post-
transplantation period (<100 days), compatible with the
previous report by Sousa et al.10 Four patients (4/57, 7%)
finally developed CMV disease, and one of them died of CMV
pneumonia with pulmonary hemorrhage and concurrent
sepsis.
Comparisons between the viremia group and the non-
viremia group revealed that older diagnostic age, leukemia,
allo-PBSCT, ATG use, GvHD, and gastrointestinal GvHD were
possible significant risk factors for CMV viremia (Table 1).
The results were compatible with those of previousPlease cite this article in press as: Wu J-L, et al., Risk factors and outc
cell transplantation patients, Journal of Microbiology, Immunology anreports.3,6,7 The allo-PBSCT regimen and ATG use were both
related to T-cell immunity destruction and delayed recov-
ery in transplantation patients.
As regards CMV serostatus, in previous studies11, donor
and recipient serostatus played a major role in post-
transplantation CMV infection. In addition, recipient sero-
positivity carries a higher risk for mortality and
morbidity.1214 Ljungman et al15 found that approximately
80% of CMV seropositive recipients may experience CMV
infection after allogeneic bone marrow transplantation
without prophylaxis. In our study, we found a high preva-
lence of CMV seropositive recipients of up to 82% (47/57).
CMV viremia incidence was 32%, which was much lower
than the results of previous studies.15 In our study, pre-
HSCT acyclovir prophylaxis may be one reason for this
phenomenon.
Allogeneic-HSCT accounts for 94% (17/18) in viremia
patients. Allogeneic-HSCT can cause marked immunosup-
pression, which interferes with T-cell reconstruction after
transplantation. The immune reconstruction process is
correlated strongly with different kinds of opportunistic
infections. Innate immunity restores rapidly after alloge-
neic HSCT, however, adaptive immunity takes much longer.
Prior to reconstruction of adaptive immunity, there is an
increased susceptibility to fungal and viral infection, such
as candida, Aspergillus, and herpes group virus.16 In a
recent review, cytotoxic pretransplantation conditioning
and posttransplantation alloreactivity are risk factors for T-
cell immune deficiency because they independently inter-
fere with normal thymus function.17 In addition, the in-
tensity of conditioning constitutes the most important
parameters influencing T-cell expansion.18 In comparisonomes of cytomegalovirus viremia in pediatric hematopoietic stem
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.011
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reduced risk of early CMV disease, myeloablative chemo-
therapy would prolong the duration of recovery of adaptive
T-cell immunity.19 For adaptive immunity or so-called
cellular immunity, much more time is needed for recovery
than for innate immunity. In patients who received man-
agements associated with T-cell or thymic damage, such as
a myeloablative regimen, total body irradiation, ATG, or
cyclosporine, the cellular immunity reconstruction would
be delayed.20 Total body irradiation was analyzed in this
study without a statistically significant difference, so the
data was not shown.
Other known risk factors, like cord blood trans-
plantation, chemotherapy with fludarabine-containing
regimens, transplantation of T-cell-depleted stem cells
(with either graft manipulation ex vivo or use of anti-T-cell
antibodies in vivo with alemtuzumab) and a low CD4 count,
and undetectable CMV-specific T-cell immunity have all
been reported previously, however, the above were not
found in this study due to no available data for these
patients.15
With regards to CMV disease in posttransplantation pa-
tients, pneumonia is the most common and serious.19,21 The
incidence of CMV pneumonia ranges from 1% to 6% in
autologous bone marrow transplantation recipients and
from 10% to 30% in allogeneic bone marrow transplantation
recipients.22 Konoplev et al21 stated that the incidence of
CMV pneumonia was significantly higher among patients
with hematological malignancies than those with solid tu-
mors (5% vs. 1%, p Z 0.019). In our study, three of four
patients with CMV diseases had hematological malig-
nancies. Jang et al23 identified several risk factors for
developing CMV diseases, including high initial viral load,
leukopenia, and neutropenia at the time of detection of
CMV viremia, and leukopenia remains an independent
predictor (pZ 0.045) on multivariate analysis. In our study,
the difference in initial viral load between the viremia-only
group and the CMV diseases group was not significant
[median, 3900 copies/mL (range, 152e15,000 copies/mL)
vs. 2025 copies/mL (range, 315e53800 copies/mL),
p Z 0.67, Mann-Whitney U test]. In addition, the highest
viral load during anti-CMV treatment in the CMV disease
group and non-CMV disease group was 3  106/mL and
2.7  107/mL, respectively (p Z 0.67).
According to a previous definition of conditioning regi-
mens,24,25 three of these four patients received myeloa-
blative conditioning chemotherapy in this study.
Myeloablative conditioning chemotherapy uses very high
doses of chemotherapy or radiation prior to transplant, to
kill nearly all of the cancer cells and normal cells in the
bone marrow, predisposing recipients to infectious com-
plications that may contribute to a poor outcome.
From Figure 2, it can be seen that the viral load of the
treated group seemed higher than that of the nontreated
group, however, it is not comparative in the figure due to
the different treatment timing of these patients. In the
nontreated group, viral load gradually decreased approxi-
mately 3 months after HSCT, which could be explained by T-
cell recovery. For the treated group, viral load several
weeks after treatment significantly decreased (pZ 0.037).
In this study, all patients received acyclovir as prophy-
laxis regimen and weekly monitoring of plasma CMV viralPlease cite this article in press as: Wu J-L, et al., Risk factors and outc
cell transplantation patients, Journal of Microbiology, Immunology anload, which is a routine program in our pediatric hemato-
oncological transplant patients. Current efforts have gone
from treatment of CMV to its prevention or preemptive
treatment. Some reports supported the benefit of prophy-
lactic ganciclovir or high dose acyclovir use,26,27 however,
rare evidence was shown in pediatric patients. In addition
to prophylaxis, preemptive therapy has been discussed for
a long time, with several documented benefits. However, it
remains controversial as to whether prophylaxis or pre-
emptive therapy is the optimal strategy for preventing CMV
disease.
There are several limitations in this study. First, this is a
retrospective chart review, and all of the information was
collected from medical records. Second, a relatively small
sample size was included with an even smaller number of
CMV disease patients. Third, posttransplantation patients
had variable diversity of disease severity and clinical con-
dition with different immunosuppressant use. All of the
above factors could interfere with the susceptibility and
severity of opportunistic infection in these patients and
further statistical results.
In conclusion, the incidences of CMV viremia and CMV
disease were high, 32% and 7%, respectively, in this study.
Viremia occurred mostly during the early post-
transplantation period (89%), usually within 100 days after
transplantation. Risk factors associated with CMV viremia
include older diagnostic age, leukemic patients, unrelated
donor HSCT, pretransplant ATG use, GvHD, and gastroin-
testinal GvHD. Monitoring of CMV viremia and early pre-
emptive therapy are recommended to reduce morbidity
and mortality in the high-risk HSCT patients.
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